Researchers have harnessed the CRISPR-Cas9 technology to correct mutations in the blood stem cells of patients with a rare immunodeficiency disorder; the engineered cells successfully engrafted in mice for up to five months.
Researchers have harnessed the CRISPR-Cas9 technology to correct mutations in the blood stem cells of patients with a rare immunodeficiency disorder; the engineered cells successfully engrafted in mice for up to five months.